Perhexiline
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Perhexiline
- Pharmacist Assessment Report
- Perhexiline: From Cardiovascular Use (Original Indication Not Recorded) to Migraine Disorder
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Perhexiline: From Cardiovascular Use (Original Indication Not Recorded) to Migraine Disorder
One-Sentence Summary
Perhexiline is an oral metabolic agent historically used as an antianginal. The Australian licence data compiled for this report do not record an approved indication. The TxGNN model predicts it may be effective for migraine disorder, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction is based on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the Australian licence data (historically used as an antianginal agent) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 0.9904 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. From general pharmacological knowledge, perhexiline inhibits carnitine palmitoyltransferase (CPT-1/CPT-2). This shifts myocardial energy metabolism from fatty acids towards glucose, which is why it was used for angina.
A link between this mechanism and migraine is speculative. Possible angles include altered neuronal energy metabolism or calcium-channel-related effects, but the data compiled for this report do not substantiate either. The high TxGNN score (0.9904) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 1822X | Pexsig | Tablet containing perhexiline maleate 100 mg (oral) | Not recorded in the data compiled |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Perhexiline has a narrow therapeutic index, and hepatotoxicity and neuropathy are recognised risks. These are general pharmacological considerations that were not supplied in the compiled data, and they would weigh heavily in any repurposing decision. No drug interaction records were found in the data compiled.
Conclusion and Next Steps
Decision: Hold
Rationale: The migraine prediction rests solely on a model score (L5), with no supporting trials, literature or established mechanistic link. Combined with perhexiline’s narrow therapeutic index and toxicity concerns, there is currently no basis to advance.
To proceed, the following is needed:
- Mechanistic evidence linking CPT inhibition or metabolic modulation to migraine pathophysiology
- Preclinical or early-phase clinical data in migraine
- The approved indication and full safety information (warnings, contraindications, interactions) from the TGA Product Information
- A risk-benefit assessment, including therapeutic drug monitoring requirements, for a non-cardiac indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.